DUBLIN, June 26, 2015 /PRNewswire/ --
Research and Markets
(http://www.researchandmarkets.com/research/7pwczx/asthma_drugs)
has announced the addition of the "Asthma Drugs Market in the US
2015-2019" report to their offering.
The analysts forecast the asthma drugs market in the US to grow
at a CAGR of 4.64% over the period 2014-2019.
The report, Asthma Drugs Market in the US 2015-2019, has been
prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its
growth prospects in the coming years. The report also includes a
discussion of the key vendors operating in this market.
Patients with persistent asthma symptoms are treated with drugs
for both symptomatic relief and as a preventive measure. This helps
in the reduction of asthma flare-ups. Generally, a patient is
prescribed LABA or leukotriene receptor antagonist (LTRA) along
with ICS. LABA and LTRA differ in their mechanisms of action but
both provide complementary benefits in combination with an ICS.
They help to manage asthma by improving lung function, reducing
symptoms, providing bronchoprotection, and controlling the
underlying inflammation.
According to the report, pharmaceutical companies are developing
drugs that have a better safety and efficacy profile than those
already available in the market. These drugs are undergoing
clinical trials or are awaiting approval by regulatory agencies.
For instance, NVA237 by Novartis and Mepolizumab by GlaxoSmithKline
are among the most promising drugs for the treatment of asthma.
Mepolizumab by GlaxoSmithKline was submitted for approval as a
maintenance treatment for severe eosinophilic asthma to the US Food
and Drug Administration (FDA) in November
2014. Tralokinumab by AstraZeneca is another promising
molecule, which is under phase III clinical trials.
Further, the report states that the unknown etiology of the
condition makes it difficult for pharmaceutical companies to
develop a curative drug for the treatment of asthma.
To calculate the market size, the report considers the
revenue generated from the sale of various classes of drugs used to
treat asthma, which include:
- Bronchodilators
- Leukotriene antagonists
- Mast cell stabilizers
- Immunosuppressants
- Combination of LABA/ICS
Key vendors
- AstraZeneca
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Merck
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Product Profiles
- Market Research Methodology
- Introduction
- Disease Overview
- Pipeline Portfolio
- Market Landscape
- Market Segmentation by Class of Drug
- Buying Criteria
- Market Growth Drivers
- Drivers and their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and Their Impact
- Vendor Landscape
- Key Vendor Analysis
For more information visit
http://www.researchandmarkets.com/research/7pwczx/asthma_drugs
Media Contact: Laura Wood
, +353-1-481-1716, press@researchandmarkets.net